Global cephalosporin drugs market projected to rise 3.34 percent
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
List view / Grid view
News
Two lots of migraine medication have been recalled
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
Leaked government document reveals possibility of no-deal Brexit drug shortages
A leaked government dossier has stated that in the event of a no-deal Brexit, the UK will face severe medicinal shortages.
OneVision: creating a global standardised laboratory network for SGS Life Sciences
SGS Life Sciences launches OneVision, a global digitalisation initiative to create a single, integrated network of testing laboratories.
MHRA consultation on application of AQbD principles enters last month
An MHRA consultation is due to end on 31 August, with public comments on AQbD principles closing soon.
FDA grants Rozlytrek cancer treatment approval
The cancer therapeutic, Rozlytrek, has gained FDA approval as well as Priority Review, Breakthrough Therapy and Orphan Drug Designations.
Silica-based drug delivery could improve anticancer drugs
Researchers have developed silica spheres to contain cancer therapeutics that melt at certain temperatures and have the potential to improve drug delivery.
Complete response letter sent for two generic products
A complete response letter (CRL) has been sent to Dr Reddy’s for two generic products.
Pharma bodies confirm signing NDAs for no-deal Brexit plans
The DHSC has confirmed that several pharmaceutical industry bodies have agreed to NDAs regarding plans for a no-deal Brexit.
Drug supplier Aspen to pay NHS £8m after competition probe
The CMA alleges that Aspen broke competition law, prompting the drug supplier to offer a payment and other compensations to the NHS.
New drug for treatment-resistant forms of tuberculosis approved
Pretomanid in combination with bedaquiline and linezolid has been approved by the FDA for treatment-resistant tuberculosis of the lungs.
Chlamydia vaccine passes safety trial
A first-of-its-kind experimental chlamydia vaccine trial has been found to be safe and able to provoke an immune response.
Imbruvica® granted expanded use from European Commission
The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström's macroglobulinemia.
FDA to deactivate out-of-date drug listings in its database
In order keep up-to-date records and protect public health the FDA has announced it intends to deactivate out-of-date drug listings.
Letter highlights issues with US drug returns verification requirements
An open letter has underscored the challenges of return failure in the US drug supply chain, especially after the introduction of the Drug Supply Chain Security Act in November.
